| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |